Takeda scraps vaccine trial in Phase II
February 2, 2015Research and Development, Sales and Marketing Diptheria-Tetanus-acellular Pertussis (DTaP) and Sabin inactivated poliovirus vaccine (sIPV), Rajeev Venkayya, TAK-361S, Takeda
Takeda has announced it is abandoning the development of a vaccine in Japan that was in Phase II clinical trials.TAK-361S, …
Sun Pharma and Ranbaxy merger gets US nod
February 2, 2015Manufacturing and Production, Sales and Marketing India, Ranbaxy, Sun Pharma, US, generics, merger, recall, torrent
The US Federal Trade Commission has given its approval for Sun Pharma’s $4 billion acquisition of troubled Indian firm Ranbaxy …
Shire drug approved for binge eating disorder
February 2, 2015Sales and Marketing ADHD, FDA, Shire, Vyvanse, binge, eating, lisdexamfetamine dimesylate, obesity
Shire has become the first company to gain FDA approval for a treatment for binge eating disorder (BED) in adults …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
Packer Forbes Communications hires director
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Packer Forbes, samantha bremner
Samantha Bremner has joined healthcare comms firm Packer Forbes as an associate director and member of the agency’s leadership team.
J&J leukaemia drug gets FDA go-ahead
January 30, 2015Sales and Marketing FDA, J&J, JJ, Janssen, The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s macroglobulinemia (WM) – a rare indol, Waldenström’s Macroglobulinemia, ibrutinab, imbruvica, johnson
The US Food and Drug Administration has shown Janssen’s leukaemia drug Imbruvica the green light to treat patients with waldenström’s …
Government spending on Tamfilu is justified
January 30, 2015Research and Development, Sales and Marketing BMJ, Lancet, Roche, Tamiflu, alltrials, oseltamivir, transparency
The most thorough analysis of Roche’s Tamiflu to date suggests that the controversial treatment can shorten the duration of flu …
BMS wins FDA approval for HIV pill
January 30, 2015Sales and Marketing BMS, Bristol-Myers Squibb, FDA, Gilead, Reyataz, atazanavir, cobicistat), evotaz, tybost
Bristol-Myers Squibb has earned FDA approval for its HIV combination treatment Evotaz. The US drugs regulator gave BMS the go-ahead …
Patients lack data confidence in NHS
January 30, 2015Medical Communications, Sales and Marketing Astellas, NHS, care data, data, online, privacy
A recent pharma survey has found that a majority of Britons lack confidence in the NHS to keep their personal …
Google partners with Biogen on multiple sclerosis
January 30, 2015Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos
Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …
Gilead makes two senior promotions
January 30, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, andrew cheng
Gilead Sciences has promoted Dr Andrew Cheng to the position of executive vice president, HIV therapeutics and development operations, and …
Scientists warn Ebola virus is mutating
January 29, 2015Research and Development, Sales and Marketing Africa, Ebola, GAVI, GSK, Institut Pasteur, J&J, JJ, guinea
Researchers in France studying the Ebola epidemic say the virus has mutated making it potentially even more contagious. Scientists based …
GSK-Novartis mega-deal signed-off by EC
January 29, 2015Research and Development, Sales and Marketing Abbott, GSK, Mylan, Novartis, acquisition, etc, merger
The European Commission has approved a GSK-Novartis M&A deal, in which GSK will purchase Novartis’ vaccines unit and Novartis will …
AstraZeneca dives into gene editing
January 29, 2015Research and Development, Sales and Marketing AstraZeneca, Intellia Therapetics, Novartis, Thermo Fisher Scientific, Wellcome Trust Sanger Institute in Cambridge, Whitehead, broad institute, crispr, the Innovative Genomics Initiative in California
AstraZeneca is looking to harness the power of a pioneering genome-editing tool in a series of new collaborations. The UK …
Roche oncology sales shine but profits dip
January 29, 2015Sales and Marketing Kadcyla, Perjeta, Roche, avastin, fourth quarter, oncology, q4
Roche has posted a mixed bag of financial results complemented only by strong growth in its oncology and immunology divisions. …
Cello Health Consulting hires Astellas head
January 29, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, Cello, cello health, jon gilbert
Healthcare marketing consultancy Cello Health Consulting has appointed pharma marketer Jon Gilbert as a senior consultant. Gilbert joins the agency …
US Supreme Court backs Teva in Copaxone patent case
January 28, 2015Sales and Marketing Copaxone, Momenta Pharmaceuticals, Mylan, Natco Pharma, Teva
Teva has won a US Supreme Court judgement allowing it to continue marketing its multiple sclerosis drug Copaxone without challenge …
Novartis sales below forecast in ‘transformative’ year
January 28, 2015Sales and Marketing Diovan, Exforge, Gleevec, Jimenez, Novartis, amlodipine, q4, valsartan
Novartis’ fourth quarter sales have faded slightly as growth in pharmaceuticals is beaten back by generic competition, and the firm …
Pfizer posts fourth-quarter revenue decline
January 28, 2015Sales and Marketing Eliquis, Lipitor, Lyrica (pregablin), Pfizer, Read, Xeljanz, apixaban, financials, pneumococcal vaccine Prevnar, q4, tofacitinib citrate
Pfizer posted a 3% decline in revenue in the last quarter of 2014, the company’s latest financial results show. The …
NICE approves world’s most expensive drug
January 28, 2015Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris
The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
